Biotech Analyst Kim holds a conference call with Dr. Sullivan, Chief Product Strategy Officer, to discuss INSM‘s TPIP (Treprostinil Palmitil Inhalation Powder): Deep Dive Ahead Of Phase 2 PAH Readout In Mid-2025.on April 9 at 1:30 pm hosted by Cantor Fitzgerald. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed’s Promising Pipeline and Market Potential Drive Buy Rating
- Insmed price target raised to $96 from $92 at BofA
- United Therapeutics price target lowered to $314 from $328 at BofA
- Innovative Gene Therapy Approach Drives Buy Rating for Insmed in DMD Treatment
- Insmed assumed with an Overweight at Morgan Stanley